Search

Your search keyword '"Millers, Andrejs"' showing total 40 results
Start Over Author "Millers, Andrejs"
40 results on '"Millers, Andrejs"'

2. Association of Schimmelpenning Syndrome with Astrocytoma (WHO Grade 3): Case Report.

Author

Tumova, Aija, Auslands, Kaspars, Millers, Andrejs, Priede, Zanda, Buks, Māris, Ozola, Agnese, Ozoliņa, Elīna, Bicāns, Kārlis, and Ulmanis, Rūdolfs

Subjects
RAS oncogenes, INTRACRANIAL tumors, NEUROCUTANEOUS disorders, SYMPTOMS, CENTRAL nervous system
Abstract

Schimmelpenning syndrome, or epidermal nevus syndrome, is a rare, neurocutaneous disorder characterized by skin abnormalities, such as epidermal nevi, and involvement of the central nervous system, including intracranial tumors. There are only a few reported cases of intracranial tumors associated with Schimmelpenning syndrome. In most cases, a single nucleotide mutation in the RAS family proto-oncogenes, like HRAS or KRAS genes, can result in the genetic mosaicism that is responsible for the clinical manifestations of this syndrome. The authors present a case report of a woman with Schimmelpenning syndrome who sought medical help with complaints of progressive headache and dizziness. The radiological and histopathological findings indicated an astrocytoma, IDH-mutant (WHO grade 3). The molecular analysis revealed pathogenic changes in the oncogenic HRAS gene with a prevalence of 31%. The patient underwent surgical treatment and had no neurological sequelae. By presenting such a clinical case, attention is paid to the interrelationship between genetic syndromes and intracranial tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up

Author

Strautmane, Sintija, primary, Balodis, Arturs, additional, Teivane, Agnete, additional, Grabovska, Dagnija, additional, Naudins, Edgars, additional, Urbanovics, Daniels, additional, Fisermans, Edgars, additional, Mednieks, Janis, additional, Flintere-Flinte, Alina, additional, Priede, Zanda, additional, Millers, Andrejs, additional, and Zolovs, Maksims, additional

Published
2023
Full Text
View/download PDF

11. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Author

Hauser, Stephen L., Bar-Or, Amit, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Montalban, Xavier, Rammohan, Kottil W., Selmaj, Krzysztof, Traboulsee, Anthony, Wolinsky, Jerry S., Arnold, Douglas L., Klingelschmitt, Gaelle, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Chin, Peter, Mairon, Nicole, Garren, Hideki, Kappos, Ludwig, And Opera Ii Clinical Investigators, Opera I., Reingold, Stephen C., Sandberg-Wollheim, Magnhild, Barkhof, Frederik, Dörmer, Thomas, Evans, Scott, Mcfarland, Henry F., Steiner, Israel, Yaldizli, Özgür, D Souza, Marcus, Andelova, Michaela, Rust, Heiko, Ballario, Carlos, Giannaula, Rolando, Reich, Edgardo Gabriel, Parratt, John, Eggers, Christian, Buyle, Maarten, Pesch, Vincent, Vanopdenbosch, Ludo, Carneiro, Denise, Friedrich, Mauricio, Longo, Alexandre Luiz, Genov, Krasimir, Ivanova, Sonya, Maslarov, Dimitar, Lilovski, Hristo, Staikov, Ivan, Cueto, German, Dufek, Michal, Havrdova, Eva, Novotna, Alena, Skoda, Ondrej, Talabova, Marika, Vachova, Marta, Gross-Paju, Katrin, Haldre, Sulev, Elovaara, Irina, Brochet, Bruno, Castelnovo, Giovanni, Clavelou, Pierre, Seze, Jerome, Debouverie, Marc, Braune, Stefan, Haas, Judith, Heidenreich, Fedor, Schwarz, Wolfgang, Siever, Arno, Urban, Peter Paul, Zettl, Uwe, Ziemann, Ulf, Ziemssen, Tjalf, Zipp, Frauke, Debreczeni, Robert, Rozsa, Csilla, Satori, Maria, Chapman, Joab, Ghezzi, Angelo, Perini, Paola, Pozzilli, Carlo, Kalnina, Jolanta, Millers, Andrejs, Budrys, Valmantas, Kizlaitiene, Rasa, Malciene, Lina, Vaitkus, Antanas, Castro Farfan, Guillermo, Gongora Rivera, Juan Fernando, Frequin, S. T. F. M., Gavidia Chucan, Jorge Martin, Perez Villegas, Julio, Pretell, Edwin Javier, Rodriguez Kadota, Liliana Elizabe, Fryze, Waldemar, Hertmanowska, Hanka, Maciejowski, Maciej, Opala, Grzegorz, Cerqueira, João, Arefieva, Elena, Maslova, Natalia, Odinak, Miroslav, Pankratov, Evgeny, Perfiliev, Semen, Poverennova, Irina, Sazonov, Denis, Shirshova, Elena, Sivertseva, Stella, Volkova, Larisa, Vorobyova, Olga, Knezevic, Zorica, Raicevic, Ranko, Vojinovic, Slobodan, Hancinova, Viera, Saffova, Patricia, Turcani, Peter, Vyletelka, Juraj, Coetzee, Christo C., Garcia-Merino, Antonio, Hernandez, Miguel A., Izquierdo Ayuso, Guillermo, Rodriguez Antigüedad, Alfredo, Gobbi, Claudio, Belal, Samir, Frih-Ayed, Mahbouba, Gouider, Riadh, Mrissa, Ridha, Sergii Moskovko, Sanotskyy, Yanosh, Sokolova, Larysa, Statinova, Olena, Voloshyna, Nataliya, Turner, Benjamin, Wilson, Martin, Applebee, Angela, Bandari, Daniel, Belkin, Martin, Birnbaum, Gary, Borresen, Thor, Boyd, James, Cascione, Mark, Cohan, Stanley, Cohen, Bruce, Conway, Jill, Cree, Bruce, Dihenia, Bhupesh, Dissin, Jonathan, Flitman, Stephen, Ford, Corey, Giancarlo, Thomas, Gold, Scott, Green, Barbara, Gwynn, Matthews, Honeycutt, David, Huddlestone, John, Klawiter, Eric, Kohrman, Bruce, Langer-Gould, Annette, Lava, Neil, Lindsey, William, Mitchell, Galen, Naismith, Robert, Nicolas, Joseph, Pardo, Gabriel, Patel, Malti, Porter, John A. H., Racke, Michael, Robertson, Derrick, Rossman, Howard, Schafer, John, Shubin, Richard, Singer, Barry, Smith, Charles, Suski, Valerie, Thrower, Ben, Wilson, Christopher, Wynn, Daniel, Zabad, Rana, Estol, Conrado J., Scarlatti, Annita, Alekseenko, Yuri, Fedulau, Aliaksandr, Kulesh, Sergey, Navumava, Halina, Willekens, Barbara, Alajbegovic, Azra, Sinanovic, Osman, Christo, Paulo, Papais Alvarenga, Regina Maria, Pereira Damasceno, Benito, Baldaranov, Dimo, Grigorova, Olga, Haralanov, Lyubomir, Milanova, Milena, Ayotte, Charles, Blevins, Gregg, Freedman, Mark, Grand Maison, François, Jacques, François, Yeung, Michael, Basic, Silvio, Hajnsek, Sanja, Janko-Labinac, Dolores, Kidjemet Piskac, Spomenka, Benesova, Yvonne, Hradilek, Pavel, Brassat, David, Edan, Gilles, Hautecoeur, Patrick, Moreau, Thibault, Papeix, Caroline, Tourbah, Ayman, Vukusic, Sandra, Aktas, Orhan, Berthele, Achim, Bodenschatz, Ralf, Foerch, Christian, Hohlfeld, Reinhard, Landefeld, Harald, Lang, Michael, Platten, Michael, Puzich, Reinhard, Schmidt, Stephan, Tubridy, Niall, Ardito, Bonaventura, Capra, Ruggero, Centonze, Diego, Crociani, Paola, Danni, Maura, Grimaldi, Luigi, Gusmaroli, Graziano, Mantegazza, Renato, Mirabella, Massimiliano, Uccelli, Antonio, Carbajal Ramirez, Angelica, Lopez Meza, Elmer Guillermo, Lopez Prieto, Juan Jose, Oropeza Alba, Jose Luis, Reyes-Morales, Sarug, San Juan Orta, Daniel, Myhr, Kjell Morten, Binek, Maciej, Czarnecki, Maciej, Klodowska-Duda, Gabriela, Stelmasiak, Zbigniew, Szczudlik, Andrzej, Tutaj, Andrzej, Belova, Anna, Dorogov, Nikolay, Fedyanin, Alexander, Khasanova, Dina, Makarov, Nikolay, Mishin, Gennadiy, Sherman, Mikhail, Skoromets, Alexander, Trushnikova, Tatiana, Donath, Vladimir, Dupejova, Beata, Gurcik, Ladislav, Arroyo, Rafael, Andres, Clara, Fernandez Fernandez, Oscar, Lainez Andrep, Jose Miguel, Martinez Gines, Maria Luisa, Martinez Rodriguez, Jose Enrique, Martinez Yelamos, Sergio, Oreja Guevara, Celia, Perez Sempere, Angel, Ramio, Luis, Ramo Tello, Cristina, Lycke, Jan, Olsson, Tomas, Roshanisefat, Homayoun, Sundström, Peter, Svenningsson, Anders, Akman Demir, Gulsen, Petek Balci, Belgin, Boz, Cavit, Efendi, Husnu, Karabudak, Rana, Siva, Aksel, Terzi, Murat, Yuceyar, Ayse Nur, Chmyr, Galyna, Goncharova, Yana, Kareta, Serhiy, Lutskiy, Igor, Harrower, Timothy, Hawkins, Clive, Pearson, Owen, Silber, Eli, Absher, John, Arnold, Thomas, Bass, Ann, Bernitsas, Evanthia, Braley, Tiffany, Calkwood, Jonathan, Carnes, Kenneth, Coyle, Patricia, Dunn, Jeffrey, Edwards, Keith, English, Jeffrey, Ferencz, Gerald, Fox, Edward, Frohman, Elliott, Gazda, Suzanne, Gitt, Jeffrey, Goodman, Andrew, Gross, Jeffrey, Hendin, Barry, Herrman, Craig, Hillen, Machteld, Huang, Deren, Hunter, Samuel, Hutton, George, Jacobs, Daniel, Keller, Bridget, Khan, Omar, Kister, Ilya, Krupp, Lauren, Lathi, Ellen, Lynch, Sharon, Miller, Tamara, Miravalle, Augusto, Omidvar, Omid, Perumal, Jai, Picone, Maryann, Rao, T. Hemanth, Repovic, Pavle, Riskind, Peter, Rowe, Vernon, Sheremata, William, Steingo, Brian, Twyman, Cary, Weisman, David, Wendt, Jeanette, Wray, Sibyl, Yapundich, Robert, Zarif, Myassar, Lääketieteen ja biotieteiden tiedekunta - Faculty of Medicine and Life Sciences, Tampere University, Hauser, S. L., Bar or, A., Comi, Giancarlo, Giovannoni, G., Hartung, H. . P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., Traboulsee, A., Wolinsky, J. S., Arnold, D. L., Klingelschmitt, G., Masterman, D., Fontoura, P., Belachew, S., Chin, P., Mairon, N., Garren, H., Kappos, L., Universidade do Minho, Willekens, Barbara, and OPERA I and OPERA II Clinical Investigators

Subjects
0301 basic medicine, Male, Esclerosi múltiple, Adult, Antibodies, Monoclonal, Humanized, Antigens, CD20, B-Lymphocytes, Brain, Disease Progression, Female, Humans, Immunologic Factors, Infusions, Intravenous, Interferon-beta, Magnetic Resonance Imaging, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Recurrence, Medicine (all), Relapsing-Remitting, Gastroenterology, Medicina Clínica [Ciências Médicas], law.invention, 0302 clinical medicine, Immunologic Factor, Randomized controlled trial, law, Monoclonal, Clinical endpoint, Infusions, Intravenou, Immunologia, Humanized, Hazard ratio, B-Lymphocyte, General Medicine, Settore MED/26 - Neurologia, Intravenous, Neurotieteet - Neurosciences, medicine.drug, Human, medicine.medical_specialty, Infusions, Multiple Sclerosis, Immunology, Antibodies, Multiple sclerosis, 03 medical and health sciences, Internal medicine, medicine, CD20, Antigens, Ciências Médicas::Medicina Clínica, business.industry, Interferon beta-1a, medicine.disease, Confidence interval, Ocrelizumab, Interferon Beta-1a, Relapsing Multiple Sclerosis, 030104 developmental biology, Monoclonal antibodies, Human medicine, business, Anticossos monoclonals, 030217 neurology & neurosurgery
Abstract

BACKGROUND B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mu g three times weekly for 96 weeks. The primary end point was the annualized relapse rate. RESULTS The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower rate with ocrelizumab; P, info:eu-repo/semantics/publishedVersion

Published
2017

13. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Author

Kappos, Ludwig, primary, Bar-Or, Amit, additional, Cree, Bruce A C, additional, Fox, Robert J, additional, Giovannoni, Gavin, additional, Gold, Ralf, additional, Vermersch, Patrick, additional, Arnold, Douglas L, additional, Arnould, Sophie, additional, Scherz, Tatiana, additional, Wolf, Christian, additional, Wallström, Erik, additional, Dahlke, Frank, additional, Achiron, Anat, additional, Achtnichts, Lutz, additional, Agan, Kadriye, additional, Akman-Demir, Gulsen, additional, Allen, Alison B, additional, Antel, Jack P, additional, Antiguedad, Alfredo Rodriguez, additional, Apperson, Michelle, additional, Applebee, Angela M, additional, Ayuso, Guillermo Izquierdo, additional, Baba, Masayuki, additional, Bajenaru, Ovidiu, additional, Balasa, Rodica, additional, Balci, Belgin Petek, additional, Barnett, Michael, additional, Bass, Ann, additional, Becker, Veit U, additional, Bejinariu, Mihaela, additional, Bergh, Florian Then, additional, Bergmann, Arnfin, additional, Bernitsas, Evanthia, additional, Berthele, Achim, additional, Bhan, Virender, additional, Bischof, Felix, additional, Bjork, Randall John, additional, Blevins, Gregg, additional, Boehringer, Matthias, additional, Boerner, Thomas, additional, Bonek, Robert, additional, Bowen, James D, additional, Bowling, Allen, additional, Boyko, Alexey N, additional, Boz, Cavit, additional, Bracknies, Vera, additional, Braune, Stefan, additional, Brescia Morra, Vincenzo, additional, Brochet, Bruno, additional, Brola, Waldemar, additional, Brownstone, Paul Kenneth, additional, Brozman, Miroslav, additional, Brunet, Donald, additional, Buraga, Ioan, additional, Burnett, Margaret, additional, Buttmann, Mathias, additional, Butzkueven, Helmut, additional, Cahill, Jonathan, additional, Calkwood, Jonathan C, additional, Camu, William, additional, Cascione, Mark, additional, Castelnovo, Giovani, additional, Centonze, Diego, additional, Cerqueira, Joao, additional, Chan, Andrew, additional, Cimprichova, Andrea, additional, Cohan, Stanley, additional, Comi, Giancarlo, additional, Conway, Jill, additional, Cooper, Joanna A, additional, Corboy, John, additional, Correale, Jorge, additional, Costell, Brian, additional, Cottrell, David A, additional, Coyle, Patricia K, additional, Craner, Matthew, additional, Cui, Liying, additional, Cunha, Luis, additional, Czlonkowska, Anna, additional, da Silva, Ana Martins, additional, de Sa, Joao, additional, de Seze, Jérôme, additional, Debouverie, Marc, additional, Debruyne, Jan, additional, Decoo, Danny, additional, Defer, Gilles, additional, Derfuss, Tobias, additional, Deri, Norma H, additional, Dihenia, Bhupesh, additional, Dioszeghy, Peter, additional, Donath, Vladimir, additional, Dubois, Benedicte, additional, Duddy, Martin, additional, Duquette, Pierre, additional, Edan, Gilles, additional, Efendi, Husnu, additional, Elias, Stanton, additional, Emrich, Peter J, additional, Estruch, Bonaventura Casanova, additional, Evdoshenko, Evgeniy P, additional, Faiss, Juergen, additional, Fedyanin, Alexander S, additional, Feneberg, Wolfgang, additional, Fermont, Jiske, additional, Fernandez, Oscar Fernandez, additional, Ferrer, Francisco Coret, additional, Fink, Katharina, additional, Ford, Helen, additional, Ford, Corey, additional, Francia, Ada, additional, Freedman, Mark, additional, Frishberg, Benjamin, additional, Galgani, Simonetta, additional, Garmany, George P, additional, Gehring, Klaus, additional, Gitt, Jeffrey, additional, Gobbi, Claudio, additional, Goldstick, Lawrence P, additional, Gonzalez, Rafael Arroyo, additional, Grandmaison, Francois, additional, Grigoriadis, Nikolaos, additional, Grigorova, Olga, additional, Grimaldi, Luigi Maria Edoardo, additional, Gross, Jeffrey, additional, Gross-Paju, Katrin, additional, Gudesblatt, Mark, additional, Guillaume, Daniel, additional, Haas, Judith, additional, Hancinova, Viera, additional, Hancu, Anca, additional, Hardiman, Orla, additional, Harmjanz, Arndt, additional, Heidenreich, Fedor R, additional, Hengstman, G J D, additional, Herbert, Joseph, additional, Herring, Mark, additional, Hodgkinson, Suzanne, additional, Hoffmann, Olaf M, additional, Hofmann, Werner E, additional, Honeycutt, William D, additional, Hua, Le Hanh, additional, Huang, Dehui, additional, Huang, Yining, additional, Huang, DeRen, additional, Hupperts, Raymond, additional, Imre, Piroska, additional, Jacobs, Alan Keith, additional, Jakab, Gabor, additional, Jasinska, Elzbieta, additional, Kaida, Kenichi, additional, Kalnina, Jolanta, additional, Kaprelyan, Ara, additional, Karelis, Guntis, additional, Karussis, Dimitrios, additional, Katz, Amos, additional, Khabirov, Farit A, additional, Khatri, Bhupendra, additional, Kimura, Takashi, additional, Kister, Ilya, additional, Kizlaitiene, Rasa, additional, Klimova, Eleonora, additional, Koehler, Juergen, additional, Komatineni, Aparna, additional, Kornhuber, Anselm, additional, Kovacs, Krisztina, additional, Koves, Agnes, additional, Kozubski, Wojciech, additional, Krastev, Georgi, additional, Krupp, Lauren B, additional, Kurca, Egon, additional, Lassek, Christoph, additional, Laureys, Guy, additional, Lee, Liesly, additional, Lensch, Eckart, additional, Leutmezer, Fritz, additional, Li, Hongzeng, additional, Linker, Ralf A, additional, Linnebank, Michael, additional, Liskova, Petra, additional, Llanera, Cristina, additional, Lu, Jiahong, additional, Lutterotti, Andreas, additional, Lycke, Jan, additional, Macdonell, Richard, additional, Maciejowski, Maciej, additional, Maeurer, Mathias, additional, Magzhanov, Rim V, additional, Maida, Eva-Maria, additional, Malciene, Lina, additional, Mao-Draayer, Yang, additional, Marfia, Girolama Alessandra, additional, Markowitz, Clyde, additional, Mastorodimos, Vasileios, additional, Matyas, Klotild, additional, Meca-Lallana, Jose, additional, Merino, Juan Antonio Garcia, additional, Mihetiu, Ioan Gheorghe, additional, Milanov, Ivan, additional, Miller, Aaron E, additional, Millers, Andrejs, additional, Mirabella, Massimiliano, additional, Mizuno, Masanori, additional, Montalban, Xavier, additional, Montoya, Lilina, additional, Mori, Masahiro, additional, Mueller, Stefanie, additional, Nakahara, Jin, additional, Nakatsuji, Yuji, additional, Newsome, Scott, additional, Nicholas, Richard, additional, Nielsen, A Scott, additional, Nikfekr, Esmaeil, additional, Nocentini, Ugo, additional, Nohara, Chiyoko, additional, Nomura, Kyoichi, additional, Odinak, Miroslav M, additional, Olsson, Tomas, additional, van Oosten, B W, additional, Oreja-Guevara, Celia, additional, Oschmann, Patrick, additional, Overell, James, additional, Pachner, Andrew, additional, Panczel, Gyula, additional, Pandolfo, Massimo, additional, Papeix, Caroline, additional, Patrucco, Liliana, additional, Pelletier, Jean, additional, Piedrabuena, Raul, additional, Pless, Misha, additional, Polzer, Udo, additional, Pozsegovits, Krisztian, additional, Rastenyte, Daiva, additional, Rauer, Sebastian, additional, Reifschneider, Gerd, additional, Rey, Roberto, additional, Rizvi, Syed A, additional, Robertson, Derrick, additional, Rodriguez, Jose Martinez, additional, Rog, David, additional, Roshanisefat, Homayoun, additional, Rowe, Vernon, additional, Rozsa, Csilla, additional, Rubin, Susan, additional, Rusek, Stanislaw, additional, Saccà, Francesco, additional, Saida, Takahiko, additional, Salgado, Antonio Vasco, additional, Sanchez, Victoria Eugenia Fernandez, additional, Sanders, Kalina, additional, Satori, Maria, additional, Sazonov, Denis V, additional, Scarpini, Elio Angelo, additional, Schlegel, Eugen, additional, Schluep, Myriam, additional, Schmidt, Stephan, additional, Scholz, Erich, additional, Schrijver, H M, additional, Schwab, Matthias, additional, Schwartz, Raymond, additional, Scott, James, additional, Selmaj, Krzysztof, additional, Shafer, Stuart, additional, Sharrack, Basil, additional, Shchukin, Ivan A, additional, Shimizu, Yuko, additional, Shotekov, Penko, additional, Siever, Arno, additional, Sigel, Karl-Otto, additional, Silliman, Scott, additional, Simo, Magdolna, additional, Simu, Mihaela, additional, Sinay, Vladimiro, additional, Siquier, Antonio Escartin, additional, Siva, Aksel, additional, Skoda, Ondrej, additional, Solomon, Andrew, additional, Stangel, Martin, additional, Stefoski, Dusan, additional, Steingo, Brian, additional, Stolyarov, Igor D, additional, Stourac, Pavel, additional, Strassburger-Krogias, Katrin, additional, Strauss, Erik, additional, Stuve, Olaf, additional, Tarnev, Ivaylo, additional, Tavernarakis, Antonios, additional, Tello, Cristina Ramo, additional, Terzi, Murat, additional, Ticha, Veronika, additional, Ticmeanu, Marina, additional, Tiel-Wilck, Klaus, additional, Toomsoo, Toomas, additional, Tubridy, Niall, additional, Tullman, Mark J, additional, Tumani, Hayrettin, additional, Turcani, Peter, additional, Turner, Ben, additional, Uccelli, Antonio, additional, Urtaza, Francisco Javier Olascoaga, additional, Vachova, Marta, additional, Valikovics, Attila, additional, Walter, Silke, additional, Van Wijmeersch, Bart, additional, Vanopdenbosch, Ludo, additional, Weber, Joerg R, additional, Weiss, Sara, additional, Weissert, Robert, additional, West, Timothy, additional, Wiendl, Heinz, additional, Wiertlewski, Sandrine, additional, Wildemann, Brigitte, additional, Willekens, Barbara, additional, Visser, L H, additional, Vorobeychik, Galina, additional, Xu, Xianhao, additional, Yamamura, Takashi, additional, Yang, Yi N, additional, Yelamos, Sergio Martinez, additional, Yeung, Michael, additional, Zacharias, Alan, additional, Zelkowitz, Marvin, additional, Zettl, Uwe, additional, Zhang, Meini, additional, Zhou, Hongyu, additional, Zieman, Ulf, additional, and Ziemssen, Tjalf, additional

Published
2018
Full Text
View/download PDF

14. PREVALENCE OF NEWLY DIAGNOSED ATRIAL FIBRILLATION AMONG PATIENTS HOSPITALIZED WITH CARDIOEMBOLIC CEREBRAL INFARCTION AT PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL, RIGA, LATVIA IN 2016.

Author

Rimicāns, Kaspars, Jurjāns, Kristaps, Miglāne, Evija, Millers, Andrejs, and Priede, Zane

Subjects
ATRIAL fibrillation, CEREBRAL infarction, DISEASE prevalence, STROKE
Abstract

Copyright of Proceedings of the International Scientific Conference of Daugavpils University / Daugavpils Universitates Starptautiskas Zinatniskas Konferences Materiali is the property of Daugavpils University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2018

15. Endovascular thrombectomy in anterior circulation stroke and clinical value of bridging with intravenous thrombolysis.

Author

Balodis, Arturs, Radzina, Maija, Miglane, Evija, Rudd, Anthony, Millers, Andrejs, Savlovskis, Janis, and Kupcs, Karlis

Abstract

Background: Bridging treatment with intravenous thrombolysis (IVT) before endovascular thrombectomy (EVT) in acute ischemic stroke is applied under the assumption of benefits for patients with large vessel occlusion (LVO). However, the benefit of this additional step has not yet been proven.Purpose: To compare procedural parameters (procedural time, number of attempts), complications, and clinical outcome in patients receiving EVT vs. patients with bridging treatment.Material and Methods: In this prospective study all patients had acute anterior cerebral circulation occlusion and were treated with EVT. All patients were selected for treatment based on clinical criteria, multimodal computed tomography (CT) imaging. Eighty-four patients were treated with bridging IVT followed by EVT; 62 patients were treated with EVT only.Results: Bridging therapy did not influence endovascular procedure time ( P = 0.71) or number of attempts needed ( P = 0.63). Bleeding from any site was more common in the bridging group (27, 32%) vs. the EVT group (12, 19%) ( P = 0.09). Functional independence modified Rankin Scale after 90 days was slightly higher in the bridging group (44%) vs. the EVT group (42%) ( P = 0.14). Mortality did not differ significantly at 90 days: 17% in the bridging group vs. 21% in EVT alone ( P = 0.57). Both treatment methods showed high recanalization rates: 94% in the bridging group and 89% for EVT alone.Conclusion: Bridging treatment in LVO did not show benefits or elevated risks of complications in comparison to EVT only. The bridging group did not show significantly better neurological outcome or significant impact on procedural parameters vs. EVT alone. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. TRANSIENT ISCHAEMIC ATTACK MIMICS AT PREHOSPITAL STAGE IN LATVIA.

Author

Vētra, Jānis, Miglane, Evija, Millers, Andrejs, Kikule, Ilga, and Dīrina, Māra

Subjects
*TRANSIENT ischemic attack, *VERTIGO, *STROKE, *HOSPITAL admission & discharge, *DIAGNOSIS
Abstract

Brief introduction. It is very important to identify Transient ischaemic attacks (TIAs) promptly because of the very high early risk of ischaemic stroke. It requires urgent investigation. TIAs have many clinical situations and diagnosis as mimics. TIA is a common diagnostic challenge at the pre-hospital stage. Materials and methods. Aim of this study was toevaluateTIA mimics at the pre-hospital stage in Latvia. This observational and retrospective study included all consecutive adult patients with prehospital diagnosis of TIA (G45 by IDC-10) referred to five hospitals in Latvia during 12 months. Referrals were considered correct if the prehospital diagnosis of TIA matched with the hospital discharge diagnosis. Results. In total, 2874 patients were included in our study. The prehospital diagnosis of TIA was correct in 14.4% cases. The most frequent mimics were vertigo (517, 17.9%), stroke (364, 12.7%), blood hypertension (295, 10.3%). In total there were 235 different hosptial discharge diagnosis. Conclusions. Transient ischaemic attacks have a high rate of mimics at prehospital stage in Latvia. The accuracy of prehospital diagnosis with hospital dicharge diagnosis is very low (14.4%). The most frequent mimics are vertigo, stroke, blood hypertension (40.9% combined). TIAs are a serious diagnostic challenge at the prehospital stage.This indicates that in Latvia there is a room and need for improvement at the prehospital TIA identification methods. [ABSTRACT FROM AUTHOR]

Published
2018

34. EFFICIENCY OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN CASES OF MYASTHENIA GRAVIS AT PAUL STRADINS CLINICAL UNIVERSITY HOSPITAL NEUROLOGY CLINIC FROM 2015 TILL 2017.

Author

Leimane, Baiba, Miglāne, Evija, and Millers, Andrejs

Subjects
*MYASTHENIA gravis, *SEROTHERAPY, *INTRAVENOUS therapy, *NEUROMUSCULAR transmission, *DISEASE duration, *MUSCLE weakness
Abstract

Introduction. Myasthenia gravis is a relatively rare autoimmune disorder caused by an antibody-induced neuromuscular transmission blockade. It causes skeletal muscle weakness. Approximately 15-20% of patients suffers from the myasthenia crisis, usually within the first 2 years from the diagnosis. One of the most effective myasthenia crisis management is intravenous immunoglobulin therapy. Materials and methods. In a retrospective study, patients diagnosed with Myasthenia gravis who received intravenous immunoglobulin therapy were selected and analyzed. The purpose of the study is to evaluate the reduction of symptoms after receiving the treatment. Patients analysis were based on clinical symptoms, duration of the disease, and complications during treatment. Results. The proportion of patients tested was significantly reduced in a few days. Some patients did not show signs of remission. Some patients did not receive a complete course of treatment in response to indirect immunoglobulin side effects. Conclusions. For most patients, treatment was effective. Effectiveness is not directly related to the onset of therapy. The severity of the symptoms is not related to efficacy. [ABSTRACT FROM AUTHOR]

Published
2018

35. Investigation of Afferent Visual Pathway Analyzing Neurodegenerative Process in Multiple Sclerosis Patients. Doctoral Thesis

Author

Pastare, Daina, Millers, Andrejs, and Laganovska, Guna

Subjects
promocijas darbs, Zinātnes nozare – medicīna, apakšnozare – neiroloģija
Abstract

Promocijas darbs izstrādāts: Paula Stradiņa Klīniskās universitātes slimnīcas Neiroloģijas un Oftalmoloģijas klīnikā. Aizstāvēšana: 2016. gada 5. decembrī plkst.15 Rīgas Stradiņa universitātes Medicīnas promocijas padomes atklātā sēdē Rīgā, Dzirciema ielā 16, Hipokrāta auditorijā. Multiplā skleroze ir hroniska autoimūna demielinizējoša un neirodeģeneratīva centrālās nervu sistēmas saslimšana. Pasaulē ir vairāk nekā divi miljoni pacientu ar multiplo sklerozi, un šī slimība ir biežākais netraumatiskas invaliditātes cēlonis gados jauniem cilvēkiem. Kaut gan multiplā skleroze ir plaši pētīta, tās patoģenēze vēl aizvien nav skaidra. Turklāt šī slimība nav pilnībā izārstējama un tās gaita katram individuālam pacientam nav prognozējama. Ir nepieciešami bioloģiskie marķieri, ar kuru palīdzību iedalīt pacientus, prognozēt un monitorēt slimības gaitu, kā arī paredzēt un kontrolēt terapijas efektivitāti. Multiplā skleroze bieži rada redzes traucējumus. Promocijas darbs “Aferento redzes ceļu izpēte neirodeģeneratīvu procesu analīzei pacientiem ar multiplo sklerozi” veltīts aferento redzes ceļu kā multiplās sklerozes klīniskā modeļa izpētei. Būtiska aferento redzes ceļu priekšrocība ir tā, ka tie ir pieejami detalizētai un tiešai strukturālai un funkcionālai izpētei. Aferentie redzes ceļi akūta redzes nerva neirīta gadījumā reprezentē akūtu centrālās nervu sistēmas bojājumu, bet subklīniskas, hroniskas retinopātijas un optiskas neiropātijas gadījumā ataino difūzu hronisku bojājumu. Promocijas darba mērķis bija izpētīt aferento redzes ceļu izmaiņu nozīmīgumu multiplās sklerozes radītu neirodeģeneratīvu procesu izvērtējumā. Pētniecības darbā tika veikti neiroloģiski, oftalmoloģiski un radioloģiski izmeklējumi 76 pacientiem ar recidivējoši remitējošu multiplo sklerozi ar un bez redzes nerva neirīta pazīmēm anamnēzē. Pētījuma rezultāti liecina, ka pacientiem ar multiplo sklerozi ir ar iepriekšēju klīnisku redzes nerva iekaisuma epizodi nesaistītas izmaiņas aferentajā redzes sistēmā. Šīs izmaiņas ir gan funkcionālas, gan strukturālas, un vērojama to savstarpēja korelācija. Turklāt neiro-deģeneratīvas izmaiņas aferentajā redzes sistēmā korelē ar slimības ilgumu, invaliditātes pakāpi, kā arī demielinizējošu perēkļu skaitu un lokalizāciju galvas smadzenēs un galvas smadzeņu atrofiju. Pētījumā noteikta labākā metode klīniska redzes nerva neirīta apstiprināšanai, kā arī izstrādāts modelis tīklenes nervu šķiedru slāņa bojājuma prognozēšanai, izmantojot funkcionālas izmeklēšanas metodes. Noskaidrots, ka aferento redzes sistēmu raksturojošus parametrus iespējams izmantot, lai iegūtu informāciju par subklīniski noritošiem neirodeģeneratīviem procesiem.

Published
2016

36. PARANEOPLASTIC NEUROPATHY COMBINATION WITH LIMBIC ENCEPHALITIS WITH POSITIVE ANTI-HU ANTIBODY. A CASE REPORT.

Author

Sabeļņikova, Santa, Flintere-Flinte, Alīna, Raita, Anita, Priede, Zanda, and Millers, Andrejs

Subjects
*PARANEOPLASTIC syndromes, *SERUM, *EARLY diagnosis, *ENCEPHALITIS, *DORSAL root ganglia, *LIMBIC system
Abstract

Anti-Hu antibody - associated paraneoplastic neurological syndromes (Hu-PNS) are presented as encephalomyelitis and/or sensory neuropathy. Paraneoplastic encephalomyelitis (PEM) is characterized by involvement of several areas of the nervous system, including temporal lobes and limbic system, brainstem, cerebellum, spinal cord, dorsal root ganglia and autonomic neuropathy. Detection of anti-Hu antibodies allow early diagnosis of PEM. We report the case of a 63-year-old woman with a two-years history of progressive leg and hand numbness and mental disturbances (short-term memory loss and difficulties with concentration and orientation). General laboratory tests showed no significant pathological findings. The neurophysiological examination suggested demyelinating polyneuropathy. Hyperintensive lesions in the medial part of thetemporal lobes were presented on the T2 and FLAIR MRI sequences. In CSF protein was slightly elevated (480.2 mg/L).The CSF microbiology was also negative. Blood serum was positive for anti-Hu antibody. As there was no evidence of specific symptoms suggesting primary malignancy, a CT scan of chest/abdomen/pelvis was performed. Enlarged mediastinal lymph nodes were found. Diagnostic videostroboscopy with lymph node biopsy was followed, but ma lignant cells were not verified. At the moment, oncological screening is ongoing and short-term immunomodulatory therapy is initiated. [ABSTRACT FROM AUTHOR]

Published
2018

37. LONG TERM HEALTH RELATED QUALITY OF LIFE AFTER CAROTID ARTERY REVASCULARIZATION OR MEDICAL THERAPY.

Author

Pucite, Elina, Krievina, Ildze, Muravska, Tatjana, Miglane, Evija, Krievins, Dainis, and Millers, Andrejs

Subjects
*QUALITY of life, *CAROTID endarterectomy, *CAROTID artery, *PEOPLE with mental illness, *SOCIAL skills
Abstract

Objectives. To evaluate health-related quality of life (HRQoL) in patients with severe carotid disease who underwent revascularization or received best medical therapy (BMT). Methods.This prospective cohort study involved 213 patients with severe carotid stenosis who underwent carotid endarterectomy - CEA (n=159), stenting - CAS (n=29) or received BMT (n=25). HRQoL was measured using SF-36v2 before revascularization, at 6 and 12 months follow-up period. Results. During the 6 and 12 months follow-up period, there weren't statistically significant changes in any of SF36v2 scores in CEA and CAS groups. In CEA group SF36v2 scores <50 were observed in general health (GH), physical (PCS) and mental (MCS) component summary domains which remained unchanged at 6 and 12 months. The highest scores (>70) in CAE group were for social functioning (SF). In CAS group SF36v2 scores <50 were in role physical (RP), GH, PCS un MCS which remained unchanged at 6 and 12 months. The highest scores (>70) in CAS group were for SF and mental health (MH) before stenting and at 6 months. In BMT group SF36v2 scores in RP became significantly lower at 6 (34.6) and 12 (37.5) months as compared with scores at the enrolment (p=0.039, rη2=0.392). Similar findings were observed in MCS where SF36v2 scores became lower after 6 (47.9) and 12 (44.5) months. Conclusions. There seems to be no major association with changes of HRQoL after CEA or CAS in one year period. The HRQoL worsened in role physical and mental component in patients who received BMT. [ABSTRACT FROM AUTHOR]

Published
2018

38. EFFECT OF CAROTID ARTERY REVASCULARIZATION ON THE COURSE OF COGNITIVE FUNCTION AND DEPRESSIVE SYMPTOMS.

Author

Pucite, Elina, Krievina, Ildze, Muravska, Tatjana, Miglane, Evija, Krievins, Dainis, and Millers, Andrejs

Subjects
*STROKE, *CAROTID artery, *CAROTID endarterectomy, *MULTI-infarct dementia, *COGNITIVE ability, *THERAPEUTICS, *CEREBRAL embolism & thrombosis, *EMOTIONAL state
Abstract

Introduction.Carotid artery disease is not just causal risk factor of ischemic stroke, but it may predispose patients to cognitive function decline and affect emotional state. The aim of the study was to evaluate long term effect of carotid artery revascularization and best medical treatment (BMT) on cognitive function and depressive symptoms. Materials and methods.ln this prospective observational cohort study 213 patients with extracranial carotid artery stenosis (≥70%) underwent assessment of cognition and depressive symptoms before carotid endarterectomy (n=159), carotid stenting (n=29) or best medical treatment (n=25) and as well as at 6 and 12 months follow-up. Results. There was statistically significant improvement of cognitive function after carotid artery endarterectomy (CEA) and stenting (CAS): median total MoCA score before endarterectomy (CEA) was 25 (IQR 22-27), 6 months after CEA - 26 (IQR 24-28), 12 months after CEA - 27 (IQR 25-29), p<0.001, Kendall's W= 0.28. Median MoCA score before CAS was 24 (IQR 21-26), after 6 months - 24.5 (IQR 21-28), after 12 months - 25 (IQR 22-28), p=0.01, Kendall's W=0.261. Statistically significant differences were not observed in BMT group: median total MoCA score at the beginning was 25 (IQR 23-26), after 6 months - 26 (IQR 23-27), after 12 months -26 (IQR 23-28). Frequencies of depressive symptoms did not change at 6 and 12 months follow-up in none of the study groups. Conclusions. High-grade carotid artery revascularization seems to exert beneficial effect on the course of cognitive function but not on the course of depressive symptoms in patients with atherosclerosis. [ABSTRACT FROM AUTHOR]

Published
2018

39. CARDIOEMBOLIC STROKE IN LATVIA: FREQUENCY, PREVENTION AND LONG-TERM OUTCOME.

Author

Jurjāns, Kristaps, Miglāne, Evija, Priede, Zanda, Kalējs, Oskars, and Millers, Andrejs

Subjects
*STROKE, *TELEPHONE interviewing, *CEREBRAL infarction, *MEDICAL history taking, *HOSPITAL admission & discharge
Abstract

Brief introduction. Cardioembolic cerebral infarction is the most severe ischemic stroke subtype, with a low frequency of symptom-free at hospital discharge, a high risk of early and late embolic recurrences, and a high mortality. Materials and methods. In a prospective study were included all 1970 patients with ischemic stroke and atrial fibrillation admitted at the P. Stradins Clinical University Hospital, Riga, Latvia from 2014 to 2017. Patients were evaluated by modified Rankins scale (mRs) were score of 0-3 considered a satisfactorily functional outcome. Patients were interviewed by phone in 30-90-180-365 days after leaving the hospital. Standardized questions were asked about patients abilities. Results. At time of discharge 48.06% patients had satisfactory functional outcome, 38.64% had severe disability and 13.30% had died in hospital. Only contacted stroke survivors (n=1842) were included in further study. In 30 days since discharge from hospital 57.16% patients had satisfactory outcome, 24.7% were severely disabled and 18.14% had died. After 90 days 60.78% of patients had satisfactory outcome, 14.68% had severe disability and 24.54% had died. In 180 days 61.47% patients were on satisfactory outcome, 7.23% had severe disability and 31.3% patients had died. Finally, after one year, 59.45% patients were on satisfactory outcome, 5.13% patients were severely disabled, and 35.42% had died. Conclusions and key words. In Latvia cardioembolic stroke one-year mortality rates are very high. Most of the patients that are severely disabled at the time of discharge die in first year since leaving the hospital. Mortality rates are significantly lower in patient groups with satisfactory stroke outcome at time of discharge. [ABSTRACT FROM AUTHOR]

Published
2018

40. The relationship between seropositivity against Chlamydia pneumoniae and stroke and its subtypes in a Latvian population.

Author

Kēniņa V, Auce P, and Millers A

Subjects
Adult, Age Factors, Aged, Aged, 80 and over, Chlamydophila Infections complications, Chlamydophila Infections epidemiology, Chlamydophila pneumoniae immunology, Female, Humans, Lithuania epidemiology, Male, Middle Aged, Retrospective Studies, Sex Factors, Stroke epidemiology, Antibodies, Bacterial blood, Chlamydophila Infections blood, Chlamydophila pneumoniae isolation & purification, Immunoglobulin G blood, Stroke blood, Stroke microbiology
Abstract

Background and Objective: Serological evidence of infection with Chlamydia pneumoniae has been associated with cardiovascular diseases, but the relationship with stroke and its risk factors remains not completely understood. The aim of this study was to determine whether serological evidence of infection with Chlamydia pneumoniae was associated with the risk of ischemic stroke and any of investigated stroke subtypes., Material and Methods: Confirmed stroke cases (n=102) were compared with gender- and age-matched control patients (n=48). The patients with stroke were divided into 3 groups according to the TOAST criteria: atherothrombotic (n=36), cardioembolic (n=47), and of undetermined etiology (n=19). Plasma levels of IgG antibodies to Chlamydia pneumoniae were measured by enzyme-linked immunosorbent assay., Results: There was a significant association between seropositivity to Chlamydia pneumoniae and stroke. Anti-Chlamydia pneumoniae IgG antibodies were detected in 64 case patients (62.7%) and 17 control patients (35.4%) (χ(2)=9.8; df=1; P=0.002). IgG seropositivity to Chlamydia pneumoniae was linked to all the analyzed etiological subtypes of stroke., Conclusion: This study showed that IgG seropositivity to Chlamydia pneumoniae was associated with stroke and all the analyzed etiological subtypes of stroke.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results